About EMulate Therapeutics
EMulate Therapeutics is a company based in Seattle (United States) founded in 2002. It operates as a HealthTech. EMulate Therapeutics has raised $23.17 million across 6 funding rounds. The company has 7 employees as of October 31, 2022. EMulate Therapeutics offers products and services including Cellsana Therapeutics, Mensana Therapeutics, and Indolor Therapeutics. EMulate Therapeutics operates in a competitive market with competitors including BetaGlue Technologies, CNRT, RITA Medical Systems, Trod Medical and Medsphere, among others.
- Headquarter Seattle, United States
- Employees 7 as on 31 Oct, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Emulate Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$23.17 M (USD)
in 6 rounds
-
Latest Funding Round
$450 K (USD), Series A
Sep 20, 2019
-
Investors
-
Employee Count
7
as on Oct 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EMulate Therapeutics
EMulate Therapeutics offers a comprehensive portfolio of products and services, including Cellsana Therapeutics, Mensana Therapeutics, and Indolor Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for glioblastoma and diffuse midline glioma offered.
Therapy for PTSD, depression, anxiety, addiction provided.
Solutions for acute and chronic pain management delivered.
Unlock access to complete
Unlock access to complete
Leadership Team
3 people
Legal and Compliance
1 people
Founder Team
1 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of EMulate Therapeutics
EMulate Therapeutics has successfully raised a total of $23.17M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $450 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $450,000
-
First Round
First Round
(12 Apr 2010)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Series A - EMulate Therapeutics | Valuation |
investors |
|
| May, 2017 | Amount | Series A - EMulate Therapeutics | Valuation |
investors |
|
| Feb, 2017 | Amount | Series A - EMulate Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by EMulate Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EMulate Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Emulate Therapeutics Comparisons
Competitors of EMulate Therapeutics
EMulate Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BetaGlue Technologies, CNRT, RITA Medical Systems, Trod Medical and Medsphere, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
A radiotherapy platform for solid tumor treatment is developed.
|
|
| domain | founded_year | HQ Location |
Medical isotopes are supplied for tumor diagnosis and treatment.
|
|
| domain | founded_year | HQ Location |
Oncology therapy products, including ablation and embolization systems, are developed.
|
|
| domain | founded_year | HQ Location |
Develops innovative RF-based focal ablation devices for tumor treatment.
|
|
| domain | founded_year | HQ Location |
Radiofrequency ablation devices for tumor treatments in organs are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Emulate Therapeutics
Frequently Asked Questions about EMulate Therapeutics
When was EMulate Therapeutics founded?
EMulate Therapeutics was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Where is EMulate Therapeutics located?
EMulate Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is EMulate Therapeutics a funded company?
EMulate Therapeutics is a funded company, having raised a total of $23.17M across 6 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Apr 12, 2010.
How many employees does EMulate Therapeutics have?
As of Oct 31, 2022, the latest employee count at EMulate Therapeutics is 7.
What does EMulate Therapeutics do?
EMulate Therapeutics is engaged in developing therapeutic devices using proprietary radio frequency energy technology, targeting low and ultra-low spectrum ranges. The company addresses unmet medical needs through subsidiaries focused on oncology, mental health, and pain management. Solutions are provided for conditions such as glioblastoma, PTSD, depression, anxiety, addiction, and chronic pain. Research and clinical trials are conducted to ensure safety and effectiveness across human and animal subjects. Multiple market opportunities are explored in cancer treatment, mental health therapies, and pain relief solutions.
Who are the top competitors of EMulate Therapeutics?
EMulate Therapeutics's top competitors include BetaGlue Technologies, CNRT and RITA Medical Systems.
What products or services does EMulate Therapeutics offer?
EMulate Therapeutics offers Cellsana Therapeutics, Mensana Therapeutics, and Indolor Therapeutics.